Translational Development Acquisition Corp.
Status: Pre-IPO
U=S+W/2
W=S@11.50
| IPO Proceeds, $M | $150.00M |
|---|---|
| IPO Date | * |
| CEO | Michael B. Hoffman |
| Left Lead | BTIG |
| IPO Cash in Trust | 100.5% |
| SPAC Tenor | 24 months |
| IPO Sector |
Healthcare
Life sciences and biotechnology |
| IPO Geography | Global |
| Target Company | TBD |
| Deal Announced | TBD |
| Deal Size, $M | TBD |
| Deal Sector | TBD |
| Deal Geography | TBD |
| SEC Filings | www.sec.gov |
| Approval Vote | TBD |
| Amendment Vote | TBD |
TDAC
TDACU
TDACW
Not listed
| Price | |
|---|---|
| Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on Translational Development Acquisition Corp.:
- Structure and cap table
- 6 directors & officers
- 3 filings and events
- 1 underwriters
Structure
Sign in to view structure, cap table, and calendar of events.
Team
| Name | Age | Title |
|---|---|---|
| Michael B. Hoffman | 72 | Chief Executive Officer & Director |
| Avanindra C. Das | 36 | Chief Financial Officer |
| E. Premkumar Reddy | 78 | Director |
| Curtis T. Keith | 51 | Director |
| Matthew A. Kestenbaum | 34 | Director |
| Christopher Jarratt | 65 | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Underwriters
| BTIG | BR | 15,000,000 | units |
| 15,000,000 | units | ||
| Up-Front UW fee | 2.00 | % | |
| Deferred UW fee |
3.50 | % |
Sign in to view more advisor data.
Filings
| Aug 26, 2022 | Initial S-1 |
| Sep 29, 2023 |
SEC Staff Action announcing abandoned registration statement
Sign In to view filing content. |
| Oct 22, 2024 | Refiled S-1 |